CME ArticlePertussis: review of epidemiology, diagnosis, management and prevention
Section snippets
Epidemiology of pertussis
Surveillance of pertussis in most countries is based on clinical notifications and laboratory reports. In developed countries with long-established vaccine programs, the general trend has been for increasing incidence with a shift to infection in older persons, although the highest incidence continues to be in infants too young to be eligible for vaccination. Comparison of pertussis incidence between countries is problematic due to differences in case definitions, access to diagnostic tests,
Possible explanations for current epidemiology
The possible reasons for the change in epidemiology leading to increasing rates in those under 5 months old and those over 10 years in developed countries with well-established immunisation programs are numerous and include the following:
- •
duration of protection and waning immunity following infection and vaccination
- •
incomplete protection from vaccination
- •
infection source for infants
- •
infection source for adolescents
- •
strain polymorphism
- •
increased diagnosis and reporting.
Diagnosis
The identification and clinical management of pertussis requires a combination of clinical suspicion, appropriate laboratory tests and consideration of antibacterial therapy (see algorithm in Table 2).
Acute pertussis infection
Infection in infants under 6 months old may require hospitalisation for supportive care of complications, for example apnoea, hypoxia or feeding difficulties. Treatment with antibiotics does not significantly shorten the clinical course in infected patients but aims to reduce transmission to other persons. In the past, erythromycin was the first-line antibiotic for pertussis treatment but it was associated with significant adverse effects including hypertrophic pyloric stenosis in infants and
Current vaccine strategies for prevention
Vaccines using inactivated whole B. pertussis organisms (Pw) of three serotypes were first developed in the 1930s and subsequently combined with diphtheria and tetanus toxoids for widespread use in immunisation programs.75 In many industrialised countries currently acellular pertussis vaccines (Pa) that include up to five antigens, (PT, FHA, PRN and two different fimbrial proteins) are used. All manufacturers include PT and PRN as sub-studies from Pa efficacy trials have implicated PT and PRN,
International collaborations
International collaborative efforts to address the rising incidence of pertussis have commenced. The GPI was created in 2001, following an educational grant from Sanofi Pasteur, and includes over 30 scientific experts from 17 countries who were divided into three regional subgroups – Europe, North America and International. The focus of this group is to raise global awareness of pertussis as an important preventable disease and to develop and communicate evidence-based recommendations for
Conclusion
Globally, pertussis remains a challenge in both developing and developed countries. In both settings, infants under 5 months of age have the highest rates of pertussis disease, morbidity and death. In developed countries widespread universal vaccination of infants has dramatically decreased the incidence of pertussis, especially hospitalisation and death, among those aged 1–10 years, but the burden of disease has shifted to older ages with adolescents and adults now most likely to transmit
Key points
- •
In countries with well-developed immunisation programs, symptomatic pertussis infections are now predominantly in the least well-immunised groups (over the age of 10 years and under 5 months).
- •
In adults and older children, diagnosis of pertussis is often delayed because classic symptoms are frequently absent, resulting in the potential to transmit infection for several weeks.
- •
The sensitivity of laboratory tests for pertussis is reduced by the use of antibiotics early in the course of infection,
Educational Aims
- •
To understand the current epidemiology of pertussis and recent changes in the burden of disease.
- •
To appreciate the different clinical presentations of pertussis in infants and adolescents.
- •
To understand the sensitivity, specificity and limitations of available laboratory investigations to diagnose pertussis infection.
- •
To understand antibiotic use in the treatment of pertussis and groups for whom prophylactic treatment is recommended.
- •
To understand the rationale underlying the different vaccination
CME Section
This article has been accredited for CME learning by the European Board for Accreditation in Pneumology (EBAP). You can receive 1 CME credit by successfully answering these questions online.
- (A)
Visit the journal CME site at http://www.prrjournal.com.
- (B)
Complete the answers online, and receive your final score upon completion of the test.
- (C)
Should you successfully complete the test, you may download your accreditation certificate (subject to an administrative charge).
References (87)
- et al.
How best to estimate the global burden of pertussis?
Lancet Infect Dis
(2003) - et al.
The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys
J Infect
(2006) - et al.
Recent developments in pertussis
Lancet
(2006) - et al.
Impact of routine vaccination with a pertussis toxoid vaccine in Denmark
Vaccine
(2004) - et al.
Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: Estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine
Vaccine
(2006) - et al.
Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine
Vaccine
(2003) - et al.
Pertussis: increasing disease as a consequence of reducing transmission
Lancet Infect Dis
(2006) - et al.
Pertussis of adults and infants
Lancet Infect Dis
(2002) Progress in the diagnosis, prevention and treatment of pertussis
Semin Pediatr Infect Dis
(2006)- et al.
Adolescent and adult pertussis vaccination: computer simulations of five new strategies
Vaccine
(2004)
The case for maternal vaccination against pertussis
Lancet Infect Dis
Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996
Clin Infect Dis
Vaccine preventable diseases and vaccination coverage in Australia, 1999–2000
Commun Dis Intell
Pertussis resurgence in Canada largely caused by a cohort effect
Pediatr Infect Dis J
Epidemiology of pertussis in French hospital in 1993–1994: thirty years after a routine use of vaccination
Pediatr Infect Dis J
New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative
Clin Infect Dis
Potential strategies to reduce the burden of pertussis
Pediatr Infect Dis J
The resurgence of pertussis in developed countries: a problem for Brazil as well?
Cad Saude Publica
Pertussis: its evolution in Argentina at the end of the twentieth century
Medicina (B Aires)
What is new in pertussis?
Eur J Pediatr
Epidemiology of pertussis
Pediatr Infect Dis J
Trends in pertussis among infants in the United States, 1980–1999
JAMA
Are vaccination programs and isolate polymorphism linked to pertussis re-emergence
Expert Rev Vaccines
Changing epidemiology and emerging risk groups for pertussis
CMAJ
The effect of changing from whole p-cell to acellular pertussis vaccine on the epidemiology of hospitalised children with pertussis in Canada
Pediatr Infect Dis J
Resurgence of pertussis in Europe
Pediatr Infect Dis J
Effectiveness of acellular pertussis vaccine assessed by hospital based active surveillance in Germany
Clin Infect Dis
Epidemiology and surveillance of pertussis among infants in Catalonia, Spain during 1997–2001
Pediatr Infect Dis J.
Bordetella pertussis surveillance in England and Wales, 1995–1997
Epidemiol Infect
Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized acellular pertussis vaccine trial
Clin Infect Dis
Population based incidence of pertussis among adolescents and adults, Minnesota 1995–1996
J Infect Dis
Mass vaccination of children with pertussis toxoid – decreased incidence in both vaccinated and non vaccinated persons
Clin Infect Dis
The seroepidemiology of pertussis in Australia during an epidemic period
Epidemiol Infect
The seroepidemiology of Bordetella pertussis infection in Western Europe
Epidemiol Infect
The epidemiology of pertussis: A comparison of the epidemiology of the disease pertussis with the epidemiology pf Bordetella pertussis infection
Pediatrics
Duration of immunity against pertussis after natural infection or vaccination
Pediatr Infect Dis J
Pertussis in Germany: regional differences in management and vaccination status of hospitalized cases
Epidemiol Infect
Cited by (169)
Discovery of a potent and selective human AC2 inhibitor based on 7-deazapurine analogues of adefovir
2023, Bioorganic and Medicinal ChemistryBordetella pertussis
2023, Molecular Medical Microbiology, Third EditionEvidence of suboptimal maternal vaccination coverage in pregnant New Zealand women and increasing inequity over time: A nationwide retrospective cohort study
2022, VaccineCitation Excerpt :Pertussis and influenza are highly contagious communicable diseases which are significant public health issues globally and in New Zealand (NZ) [2]. In 2018, greater than150,000 cases of pertussis occurred globally [3] and pertussis remains one of the top 10 causes of infant mortality worldwide with an estimated 24 million cases and 160,000 deaths annually in children younger than 5 years [4,5]. NZ has a pertussis epidemic cycle every four to five years, the last one in 2017–2018 resulted in over 4,200 cases.
Hfq modulates global protein pattern and stress response in Bordetella pertussis
2020, Journal of ProteomicsCitation Excerpt :Mutants lacking Hfq display reduced virulence and an increased sensitivity to nutrient starvation, oxidative stress, high osmolarity, and antimicrobial peptides [13–16]. Hfq is also a relevant regulator in B. pertussis [17–19], the etiological agent of the whooping cough (pertussis), a highly contagious respiratory disease which remains a serious public health problem despite the high vaccine coverage worldwide [20]. B. pertussis is a strictly human pathogen that expresses a variety of virulence factors critical for host colonization [21] and persistence within host cells [22].